JO
FDMT icon

John Overdeck’s 4D Molecular Therapeutics FDMT Stock Holding History

John Overdeck’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$924K Sell
69,481
-54,836
-44% -$534K ﹤0.01% 3675
2026
Q1 		$1.16M Sell
124,317
-213,186
-63% -$1.86M ﹤0.01% 3153
2025
Q4 		$2.53M Buy
337,503
+64,007
+23% +$649K ﹤0.01% 2271
2025
Q3 		$2.38M Sell
273,496
-257,667
-49% -$1.54M ﹤0.01% 2017
2025
Q2 		$1.97M Buy
531,163
+69,706
+15% +$245K ﹤0.01% 1842
2025
Q1 		$1.49M Buy
461,457
+147,464
+47% +$695K ﹤0.01% 1927
2024
Q4 		$1.75M Buy
313,993
+208,021
+196% +$1.63M ﹤0.01% 1808
2024
Q3 		$1.15M Buy
105,972
+78,449
+285% +$1.3M ﹤0.01% 2046
2024
Q2 		$578K Sell
27,523
-3,878
-12% -$97.3K ﹤0.01% 2303
2024
Q1 		$1M Buy
+31,401
New +$801K ﹤0.01% 1959
2023
Q4 		– Sell
-101,863
Closed -$1.3M – 3218
2023
Q3 		$1.3M Sell
101,863
-83,276
-45% -$1.39M ﹤0.01% 1786
2023
Q2 		$3.35M Sell
185,139
-15,744
-8% -$290K 0.01% 1127
2023
Q1 		$3.45M Buy
200,883
+46,909
+30% +$912K 0.01% 1078
2022
Q4 		$3.42M Buy
153,974
+137,525
+836% +$2.12M 0.01% 1049
2022
Q3 		$132K Sell
16,449
-29,546
-64% -$268K ﹤0.01% 2190
2022
Q2 		$321K Buy
45,995
+30,295
+193% +$295K ﹤0.01% 2005
2022
Q1 		$237K Sell
15,700
-55,147
-78% -$866K ﹤0.01% 2293
2021
Q4 		$1.55M Buy
+70,847
New +$1.74M ﹤0.01% 2151

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

John Overdeck's FDMT Position: Q2 2026 in Review

John Overdeck reduced its 4D Molecular Therapeutics (FDMT) stake by 44% in Q2 2026, selling an estimated $534K and leaving 69,481 shares worth $924K. The position accounts for ﹤0.01% of the portfolio, ranked #3675.

John Overdeck first reported a position in FDMT in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.45M in Q1 2023. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • John Overdeck held 69,481 shares of 4D Molecular Therapeutics worth $924K as of Q2 2026.
  • John Overdeck sold 54,836 4D Molecular Therapeutics shares in Q2 2026, an estimated $534K.
  • 4D Molecular Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3675 holding.
  • John Overdeck first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • John Overdeck's 4D Molecular Therapeutics position peaked at $3.45M in Q1 2023.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.